Óskar Ö. Hálfdánarson

Óskar Ö. Hálfdánarson

Auto-generated profile, based on publicly available information

Óskar Ö. Hálfdánarson

Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ÓHÓskar Hálfdánarson
Óskar Hálfdánarson
HZHelga Zoëga
Helga Zoëga
LALise Aagaard
Lise Aagaard
MBMiquel Bernardo
Miquel Bernardo
LBLena Brandt
Lena Brandt
CBChristian J Bachmann
Christian J Bachmann

1 January 2018 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
ÓHÓskar Ö. Hálfdánarson
Óskar Ö. Hálfdánarson
APAnton Pottegård
Anton Pottegård
EBEinar S. Björnsson
Einar S. Björnsson
SLSigrún H. Lund
Sigrún H. Lund
MOMargret H. Ogmundsdottir
Margret H. Ogmundsdottir
HZHelga Zoega
Helga Zoega
The use of proton-pump inhibitors (PPIs) has grown worldwide, and there are concerns about increased unsubstantiated long-term use. The aim of the study was to describe the real-world use of PPIs over the past decade in an entire national population. This was a nationwide population-based drug-utilization study. Patterns of outpatient PPI use among adults in Iceland between 2003 and 2015 were investigated, including annual incidence and prevalence, duration of use, and dose of tablet used (lower versus higher), as well as the proportion of PPI use attributable to gastroprotection. We observed 1,372,790 prescription fills over the entire study period, of which 95% were for higher-dose PPIs. Annual incidence remained stable across time (3.3–4.1 per 100 persons per year), while the annual prevalence increased from 8.5 per 100 persons to 15.5 per 100 persons. Prevalence increased with patient age and was higher among women than men. Duration of treatment increased with patients’ age (36% of users over 80 years remained on treatment after 1 year compared with 13% of users aged 19–39 years), and was longer among those initiating on a higher dose compared with a lower dose. The proportion of PPI users concurrently using nonsteroidal anti-inflammatory drugs decreased over the study period, while the proportion concurrently using acetylsalicylic acid, oral anticoagulants, or platelet inhibitors increased. In this nationwide study, a considerable increase in overall outpatient use of PPIs over a 13-year period was observed, particularly among older adults. Patients were increasingly treated for longer durations than recommended by clinical guidelines and mainly with higher doses.

22 November 2021 in Evidence Based Mental Health
Verified
Journal Article
Open access
PDF file
ÓHÓskar Hálfdánarson
Óskar Hálfdánarson
JCJacqueline M Cohen
Jacqueline M Cohen
ØKØystein Karlstad
Øystein Karlstad
CCCarolyn Cesta
Carolyn Cesta
MBMarte-Helene Bjørk
Marte-Helene Bjørk
HZHelga Zoega
Helga Zoega
Background: Antipsychotics are increasingly used among women of childbearing age and during pregnancy. Objective: To determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders. Design Population-based cohort study, including a sibling analysis. Setting Nationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016). Participants 4 324 086 children were eligible for inclusion to the study cohort. Intervention Antipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use. Main outcome measures Non-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors. Findings: Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD. Discussion: Our findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics. Clinical implications: Results regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.

19 December 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
ÓHÓskar Ö. Hálfdánarson
Óskar Ö. Hálfdánarson
KFKatja Fall
Katja Fall
MOMargret H. Ogmundsdottir
Margret H. Ogmundsdottir
SLSigrún H. Lund
Sigrún H. Lund
ESEiríkur Steingrímsson
Eiríkur Steingrímsson
HZHelga Zoega
Helga Zoega

23 December 2019 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
ÓHÓskar Ö. Hálfdánarson
Óskar Ö. Hálfdánarson
APAnton Pottegård
Anton Pottegård
SLSigrún H. Lund
Sigrún H. Lund
MOMargret H. Ogmundsdottir
Margret H. Ogmundsdottir
HOHelga M. Ogmundsdottir
Helga M. Ogmundsdottir
HZHelga Zoega
Helga Zoega